◈ Nootpedia
Compact view
Research pass: medium Supplement · Capsule SKIP-FOR-NOW LOW

Liposomal Glutathione

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW LOW

NAC 1200 mg + glycine in V4 already drives endogenous GSH synthesis with stronger evidence base and lower cost; liposomal GSH addresses GI bioavailability but not BBB delivery, and the brain protection thesis is the priority. Verdict would flip if a chronic-NAC failure profile emerges (no objective GSH/oxidative-stress improvement on bloodwork) or if a credible RCT lands showing CNS GSH elevation from oral liposomal GSH.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW LOW

    NAC 1200 mg + glycine 3 g already in V4 cover endogenous GSH synthesis with the substrate machinery localized to brain. Liposomal GSH adds peripheral GSH but no validated brain delivery. Cost + redundancy don't justify the slot.

  • 30-50, executive maintenance
    O

    add at 500 mg/day if oxidative stress markers elevated (8-isoprostane, oxidized LDL) and lifestyle exposure high (alcohol, pollution, mold). Otherwise NAC + glycine + diet first.

  • 50+, mild cognitive decline
    C

    GlyNAC protocol first (NAC + glycine, Sekhar dosing). GlyNAC has the actual cognitive RCT data in older adults. Liposomal GSH only if NAC tolerance issue.

  • Anxiety-prone
    N

    NAC has an OCD/trichotillomania literature base; liposomal GSH does not.

  • High athletic load, tested status
    O

    add. Heavy training elevates oxidative stress; peripheral GSH support is reasonable. Not WADA-banned. NAC is cheaper and equally effective for this purpose.

  • Sleep-disordered
    I

    axis.

  • Recovery-focused (post-injury, post-illness)
    R

    PRN — mobilizes GSH stores during high oxidative load. 1000 mg/day × 2-4 weeks during recovery window.

  • Strength/anabolic-focused
    M

    NAC covers it.

  • Documented GSTM1/GSTT1 null + high toxin exposure (mold, heavy metals)
    S

    case. This is the user profile where liposomal GSH earns a slot.

▸ Subjective experience (deep)

Mostly subtle. Onset is typically not acute; expect 1-3 weeks before any noticeable shift. Reported effects (when present): slight mood lift, better skin clarity, less foggy on hangovers (irrelevant for Dylan, zero alcohol), faster recovery from illness, better tolerance to environmental toxin exposure (mold, alcohol, pollution). Not a "nootropic feel" compound — no acute focus, energy, or cognition signal. If you take it expecting modafinil-like effects, you will conclude it does nothing.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: None described. GSH is a substrate, not a receptor agent — no downregulation pathway.
  • Recommended cycle: Continuous use is fine; cycling not mechanistically required.
  • Reset: N/A.
▸ Stacking deep dive

Synergistic with

  • n-acetyl-cysteine: Provides cysteine substrate for endogenous GSH synthesis — works through a different door than direct GSH delivery. Together, NAC handles brain side + substrate replenishment, liposomal GSH handles peripheral + acute GSH demand. However, this is mechanistically redundant for most goals; pick one.
  • Vitamin C (V4): Recycles oxidized GSH back to reduced form via the GSH-ascorbate cycle.
  • Selenium: Cofactor for glutathione peroxidase (GPx) — without selenium, GSH can't do its peroxide-quenching job.
  • Alpha-lipoic acid (R-ALA): Recycles GSH and crosses cell membranes; classic antioxidant network partner.
  • taurine: Complementary antioxidant with osmolyte + membrane-stabilizing roles; non-redundant.
  • Curcumin (V4): Upregulates Nrf2 → endogenous GSH synthesis machinery.

Avoid stacking with

  • s-acetyl-glutathione: Redundant — both are oral GSH delivery formats. Pick one. Liposomal has stronger PK data.
  • Direct plain oral GSH: Wasted money — PK is poor.

Neutral / safe co-administration

Compatible with all of V4. No interactions with modafinil, nootropic peptides, racetams, or stimulants.

▸ Drug interactions deep dive
  • Cisplatin / chemotherapy: GSH antagonizes some chemotherapy mechanisms — discuss with oncologist (irrelevant for Dylan).
  • Acetaminophen overdose: GSH (and NAC) is part of the antidote, not a contraindication — hepatoprotective.
  • CYP enzymes: GSH is not a major CYP modulator at supplement doses. Glutathione conjugation (phase II) handles its own substrates without affecting CYP-driven drug metabolism meaningfully.
  • Hormonal contraceptives: No known interaction.
▸ Pharmacogenomics
  • GSTM1 / GSTT1 null genotypes: ~50% of the population has a deletion of one or both glutathione-S-transferase genes; these individuals have impaired phase II conjugation and theoretically benefit more from GSH support. Dylan's 23andMe results (June 2026) will reveal status. If GSTM1/GSTT1 null, the case for GSH support strengthens — but NAC still covers it.
  • GCLC / GCLM polymorphisms: Affect rate-limiting GCL enzyme for endogenous synthesis. Variants associated with lower baseline GSH may benefit more from substrate (NAC + glycine) than from direct GSH.
  • GPX1 (Pro198Leu): Affects glutathione peroxidase activity; selenium repletion matters more than GSH dose here.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC / liquid Quicksilver Scientific (1.7 oz, 100 mg per 2 pumps, 50 servings) $45/bottle ≈ $45-90/mo at 100-200 mg/day, $90-135/mo at 500 mg/day High Lemon mint or cacao mint flavor; sublingual hold recommended
OTC / liquid ReadiSorb (4 fl oz drink) ~$50-65/bottle, ~$50/mo at standard dose High Long-standing brand, soy lecithin liposome
OTC / powder packets ReadiSorb GO (30 × 500 mg packets) ~$70-90/box = $70-90/mo at 500 mg/day High Travel-friendly, single-serve
OTC / capsule Pure Encapsulations Liposomal-S (also Designs for Health) ~$40-60/mo High Capsule format, easier compliance, slightly less PK than liquid
OTC / capsule Nootropics Depot (when stocked) ~$30-40/mo High Third-party tested; Dylan's preferred OTC vendor

Practical monthly: $40-90/mo depending on form and dose. Quicksilver and ReadiSorb are the well-cited brands with actual liposome characterization; cheaper "liposomal" capsule products often have unverified vesicle integrity.

▸ Biomarkers to track (deep)
  • Baseline (before starting):
    • RBC glutathione (Genova or Quest)
    • GSH/GSSG ratio (oxidized:reduced)
    • 8-isoprostane (urine, oxidative stress)
    • hs-CRP, IL-6 (inflammation)
    • ALT, AST, gamma-GT (liver, secondary GSH demand marker)
    • Urinary mercury / lead / arsenic (if mobilization rationale)
  • During use: Recheck at 8 weeks. Same panel. If RBC GSH and GSH/GSSG don't improve, formulation isn't working OR baseline wasn't deficient.
  • Post-cycle (if cycled): N/A — continuous use.
▸ Controversies / open debates Live debate

  1. Liposomal vs S-acetyl vs sublingual vs IV: The Sinha 2018 numbers are impressive but open-label and industry-adjacent. The 2024-2025 crossover (MDPI Antioxidants) confirms liposomal advantage but in a small sample. There is no head-to-head dose-equivalent RCT vs NAC + glycine showing superiority for any clinical endpoint. Bottom line: liposomal beats plain oral GSH; whether it beats NAC + glycine for the same money is unproven.

  2. BBB delivery claim: Marketing routinely states liposomal GSH "crosses the BBB" by extrapolating from GSH-conjugated drug-delivery liposome research. This is a category error. The supplement is GSH-cargo-inside-phospholipid; the BBB research is GSH-conjugated-on-outside-of-PEG-liposome carrying a drug. Different architectures, different mechanisms. The supplement form has no human RCT showing brain GSH elevation.

  3. GlyNAC primary endpoint failure (Frontiers 2022): A 2-week RCT in healthy adults FAILED the primary endpoint. This complicates the "NAC + glycine is well-established" narrative — in young healthy people with normal GSH, substrate doesn't move much. Sekhar's older-adult trials show benefit because older adults are GSH-deficient at baseline. Implication for Dylan: at 20 with no documented deficiency, ANY GSH-modulating supplement (NAC, glycine, liposomal) may show small effects until a deficit is documented on bloodwork.

  4. Is V4's glycine dose adequate for GSH synthesis? V4 has glycine at 3 g/day (currently flagged for replacement with L-tryptophan for sleep purposes). 3 g is a reasonable substrate dose. If glycine is dropped, the case for GSH support — either liposomal GSH or restored glycine — gets slightly stronger. The Sekhar protocol uses ~100 mg/kg/day glycine (~7-9 g for Dylan), much higher than V4.

  5. My prior verdict humility: The encyclopedia entry for liposomal GSH already says "skip — NAC handles brain side." That stands, but with a soft asterisk: if June 2026 bloodwork reveals low RBC GSH despite NAC 1200 mg, that's the trigger to reconsider — first by adding back glycine or going to GlyNAC dosing, then liposomal GSH only if substrate path fails.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW LOW. NAC 1200 mg in V4 covers brain GSH path; glycine in V4 covers second substrate. Liposomal GSH solves GI bioavailability but not BBB; cognitive RCTs absent; cost $40-90/mo for marginal redundant coverage. Trigger to reconsider: chronic NAC failure on bloodwork (low RBC GSH, high oxidative stress despite NAC compliance), or GSTM1/GSTT1 null + high oxidative load on June 2026 panel.
▸ Open questions / gaps Open
  1. Does oral liposomal GSH raise brain GSH in humans? No published evidence. This is THE question that would change the verdict for a brain-priority user.
  2. Head-to-head: liposomal GSH 500 mg/day vs NAC 1200 mg + glycine 3 g — which raises GSH/GSSG more in healthy young adults? Not done.
  3. Does it matter for Dylan specifically given subconcussive impact exposure? Speculative — TBI literature suggests acute GSH depletion post-impact, and NAC has some TBI evidence (Hoffer 2013, soldiers with mild TBI). Liposomal GSH has no TBI evidence.
  4. GSTM1/GSTT1 status: Flag for June 2026 23andMe interpretation. Null status would shift the case slightly toward direct GSH delivery.
  5. Does V4 glycine being replaced with L-tryptophan create a substrate gap? Diet has glycine (collagen, gelatin, chicken skin); 3 g supplemental is a meaningful but not load-bearing input. Track on bloodwork.
▸ Sources (full, with our context)
Back to compact view